| Guanzhong Zhang,Zhaozhe Liu,Tao Han,Fang Guo,Qingqing Sun,Yanan Ge,Yaling Han,Xiaodong Xie. Treatment of etoposide capsule combined with cisplatin or carboplatin in elderly patients with small cell lung cancer. Oncol Transl Med, 2014, 13: 528-531. |
| Treatment of etoposide capsule combined with cisplatin or carboplatin in elderly patients with small cell lung cancer |
| Received:September 11, 2014 Revised:November 03, 2014 |
| View Full Text View/Add Comment Download reader |
| KeyWord:small cell lung cancer (SCLC); etoposide capsule; cisplatin; carboplatin; elderly |
| Author Name | Affiliation | E-mail | | Guanzhong Zhang | Oncology Department, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China 110016 | gzzhang2009@126.com | | Zhaozhe Liu | Oncology Department, General Hospital of Shenyang Military Region, Shenyang, Liaoning, China 110016 | lzz_summer@126.com | | Tao Han | Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning | | | Fang Guo | Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning | | | Qingqing Sun | Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning | | | Yanan Ge | Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning | | | Yaling Han | Cardiovascular disease institute,General Hospital of Shenyang Military Region,Shenyang,Liaoning | | | Xiaodong Xie | Oncology Department,General Hospital of Shenyang Military Region,Shenyang,Liaoning | doctor_xxd@163.com |
|
| Hits: 8944 |
| Download times: 8832 |
| Abstract: |
| Objective: We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to November 2013, 32 elderly patients (71–79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region (China) were enrolled in the research. The patients were administrated with lastet capsule 150–175 mg, d1–5, combined with cisplatin 20 mg/m2 d1–3 or carboplatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results: After treatments, 2 cases acquired complete response (CR), 19 cases acquired partial response (PR), 8 cases acquired stable disease (SD), and 3 cases had progression of disease (PD). The objective response rate was 65.6% (21/32), disease control rate was 90.6% (29/32). The median time of progression-free survival (PFS) was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of I/II leukopenia and astrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC. |
| Close |
|
|
|